[HTML][HTML] Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment

J Park, Y Choi, H Chang, W Um, JH Ryu, IC Kwon - Theranostics, 2019 - ncbi.nlm.nih.gov
The use of nanomedicine for cancer treatment takes advantage of its preferential
accumulation in tumors owing to the enhanced permeability and retention (EPR) effect. The …

Resistance to trastuzumab

S Vivekanandhan, KL Knutson - Cancers, 2022 - mdpi.com
Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …

The role of PET/CT in breast cancer

B Hadebe, L Harry, T Ebrahim, V Pillay, M Vorster - Diagnostics, 2023 - mdpi.com
Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer
worldwide, with an estimated 2.3 million new cases (11.7%), followed by lung cancer …

Optimal control theory for personalized therapeutic regimens in oncology: Background, history, challenges, and opportunities

AM Jarrett, D Faghihi, DA Hormuth, EABF Lima… - Journal of clinical …, 2020 - mdpi.com
Optimal control theory is branch of mathematics that aims to optimize a solution to a
dynamical system. While the concept of using optimal control theory to improve treatment …

A hybrid model of tumor growth and angiogenesis: In silico experiments

CM Phillips, EABF Lima, RT Woodall, A Brock… - Plos one, 2020 - journals.plos.org
Tumor associated angiogenesis is the development of new blood vessels in response to
proteins secreted by tumor cells. These new blood vessels allow tumors to continue to grow …

Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer

AS Kazerouni, DA Hormuth, T Davis, MJ Bloom… - Cancers, 2022 - mdpi.com
Simple Summary Tumor heterogeneity influences tumor progression and response to
therapy, introducing a significant challenge in the treatment of breast cancer. We employed …

Optimizing combination therapy in a murine model of HER2+ breast cancer

EABF Lima, RAF Wyde, AG Sorace… - Computer methods in …, 2022 - Elsevier
Human epidermal growth factor receptor 2 positive (HER2+) breast cancer is frequently
treated with drugs that target the HER2 receptor, such as trastuzumab, in combination with …

Multiparametric analysis of longitudinal quantitative MRI data to identify distinct tumor habitats in preclinical models of breast cancer

AK Syed, JG Whisenant, SL Barnes, AG Sorace… - Cancers, 2020 - mdpi.com
This study identifies physiological tumor habitats from quantitative magnetic resonance
imaging (MRI) data and evaluates their alterations in response to therapy. Two models of …

Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer

AM Jarrett, MJ Bloom, W Godfrey… - … and biology: a …, 2019 - academic.oup.com
The goal of this study is to develop an integrated, mathematical–experimental approach for
understanding the interactions between the immune system and the effects of trastuzumab …

Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer

AM Jarrett, A Shah, MJ Bloom, MT McKenna… - Scientific reports, 2019 - nature.com
The goal of this study is to experimentally and computationally investigate combination
trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing …